
TELA Stock Forecast & Price Target
TELA Analyst Ratings
Bulls say
TELA Bio is showing strong Y/Y growth with Q4/25 revenue up 18% and a steady increase in customer additions and OUS sales growth. While gross margin of 65.9% was slightly below analyst estimates, EPS of ($0.17) exceeded expectations. The company's innovative OviTex portfolio is expected to continue driving sales growth as it targets various surgical procedures within soft-tissue reconstruction.
Bears say
TELA Bio is facing challenges in the market that is leading to a slowdown in its sales growth, which management attributes to their own strategic overhaul that is taking longer than anticipated to have an impact. The recent updates and changes to the company's commercial team and go-to-market strategy have yet to fully materialize, and there is still a lot of work to be done in terms of execution. Additionally, with a significant portion of the sales force being newly hired and a new territory strategy in place, there is a risk of disruption and potential loss of surgeons to competitors. Given these factors, the company has significantly lowered its sales growth outlook and faces pressure to demonstrate its ability to execute and regain investor confidence.
This aggregate rating is based on analysts' research of TELA Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.
TELA Analyst Forecast & Price Prediction
Start investing in TELA
Order type
Buy in
Order amount
Est. shares
0 shares